Beyond Remission: Rationale and Design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study

CNS Spectrums

Volumn 11, Issue S15, 2006, Pages 28-34

  Kornstein, Susan G ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; VENLAFAXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTORY, ANCIENT; HUMANS; RECURRENCE;

EID: 33845799171     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900015236     Document Type: Article

References (22)

1. Kupfer, DJ. Long-term treatment of depression. J Clin Psychiatry. 1991; 52(suppl):28–34.
2. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2000; vii–87.
3. Judd, LL, Paulus, MJ, Schettler, PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000; 157: 1501–1504.
4. Mueller, TI, Leon, AC, Keller, MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999; 156: 1000–1006.
5. Frank, E, Kupfer, DJ, Perel, JM, et al. Three-year outeomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990; 47: 1093–1099.
6. *D clinical trial. J Psychiatr Res. 2006; 40: 59–69.
7. Montgomery, SA, Entsuah, R, Hackett, D, Kunz, NR, Rudolph, RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004; 65: 328–336.
8. Keller, MB, Kocsis, JH, Thase, ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998; 280: 1665–1672.
9. Lustman, PJ, Clouse, RE, Nix, BD. et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006; 63: 521–529.
10. Detke, MJ, Wiltse, CG, Mallinckrodt, CH, McNamara, RK, Demitrack, MA, Bitter, I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14: 457–470.
11. Gelenberg, AJ, Trivedi, MH, Rush, AJ, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003; 54: 806–817.
12. Gilaberte, I, Montejo, AL, de la Gandara, J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol. 2001; 21: 417–424.
13. Klysner, R, Bent-Hansen, J, Hansen, HL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2002; 181: 29–35.
14. Miner, CM, Brown, EB, Gonzales, JS, Munir, R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry. 2002; 63: 232–240.
15. Rouillon, F, Warner, B, Pezous, N, Bisserbe, JC. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol. 2000; 15: 133–140.
16. Lenze, EJ, Dew, MA, Mazumdar, S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment. Am J Psychiatry. 2002; 159: 466–468.
17. Fava, GA, Ruini, C, Rafanelli, C, Finos, L, Conti, S, Grandi, S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry. 2004; 161: 1872–1876.
18. Solomon, DA, Leon, AC, Mueller, TI, et al. Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry. 2005; 66: 283–290.
19. Posternak, MA, Zimmerman, M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J Clin Psychiatry. 2005; 66: 705–707.
20. Rush, AJ, Koran, LM, Keller, MB, et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry. 1998; 59: 589–597.
21. Thase, ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997; 58: 393–398.
22. Simon, JS, Aguiar, LM, Kunz, NR, Lei, D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004; 38: 249–257.